Why MicroAlgo & WiMi Hologram Cloud Shares Are Jumping Premarket Today

MicroAlgo Inc. and WiMi Hologram Cloud Inc. are partnering to create a research center focused on the relationship between consciousness and quantum mechanics, with the aim of becoming an international hub for quantum information science and AI.

MicroAlgo Inc. (NASDAQ:MLGO) and WiMi Hologram Cloud Inc. (NASDAQ:WIMI) shares are surging premarket today after the companies partnered to create a micro-consciousness quantum research center.

As per the deal, this center will utilize quantum theory and cutting-edge AI technology to study the relationship between consciousness and quantum mechanics to explore deep scientific concepts, unify quantum theory with human consciousness, and push the boundaries of scientific understanding.

Notably, the center will integrate disciplines such as physics, mathematics, medicine, computer science, biology, polymer chemistry, psychology, and sociology to form a comprehensive institute focused on consciousness research.

The micro-consciousness quantum research center’s core research areas include quantum computing and consciousness modeling, brain-computer interface technology, big data AI and quantum consciousness, and quantum-driven generative consciousness.

The center aims to integrate top resources and gather talent worldwide, aspiring to become an international innovation hub for quantum information science, artificial intelligence, neuroscience, and biology.

Price Action: MLGO shares jumped 166.7% at $4.16 and WIMI shares are up 17.4% at $1.01 premarket at the last check Tuesday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo via Shutterstock

Total
0
Shares
Related Posts
Read More

Aptorum Group Announces Publication Of A Co-Authored Paper On Its PathsDx Technology, A Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow For Liquid Biopsy Based Diagnosis Of Infectious Diseases On Illumina Platforms

Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune and infectious diseases, is pleased to announce

APM